An Overview of the Biopharmaceutics Classification System (BCS)
Centre for Pharmaceutical Sciences, UCESTH, JNTUH, Hyderabad, India.
Review Article
GSC Biological and Pharmaceutical Sciences, 2021, 14(02), 217–221.
Article DOI: 10.30574/gscbps.2021.14.2.0012
Publication history:
Received on 11 January 2021; revised on 12 February 2021; accepted on 15 February 2021
Abstract:
The Biopharmaceutics Classification System (BCS) is an essential tool in pharmaceutical sciences, providing a scientific framework for classifying drugs based on their solubility and permeability characteristics. This system, developed in 1995, helps streamline drug development and regulatory approval processes by predicting in vivo drug performance from in vitro data. This paper reviews the four BCS classes, their solubility and permeability criteria, detailed procedures for determining these characteristics, and suitable formulation strategies for each class. Additionally, it explores the concept of biowaivers, which allows for the waiver of in vivo bioavailability and bioequivalence studies under certain conditions, primarily for BCS Class I drugs. The advantages, challenges, and limitations of biowaivers are discussed, emphasizing the need for global harmonization to fully realize the BCS's potential.
Keywords:
Biopharmaceutics Classification System (BCS); Biowaivers, solubility; Permeability; Drug development; Regulatory approval; Drug classification; Oral solid dosage forms; Bioavailability; bioequivalence
Full text article in PDF:
Copyright information:
Copyright © 2021 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0
